Since its injectable medication Stelara, which generated over $10 billion in sales last year, is up against fierce competition from less expensive competitors, J&J has been developing more practical psoriasis treatment choices.When compared to a placebo and Bristol's Sotyktu at weeks 16 and 24, the pharmaceutical company claimed that its oral medication, icotrokinra, achieved both primary and secondary objectives in the studies' adult participants.
Icotrokinra did not exhibit any new safety signals and its adverse event rates were comparable to those of a placebo. For people who are candidates for systemic therapy and have moderate-to-severe plaque psoriasis, Bristol's Sotyktu has previously received approval. In 2024, the medicine brought in $246 million. around 2028, J&J had originally projected that icotrokinra would bring around $700 million in sales.
J&J is evaluating its medication on adults and children with moderate-to-severe plaque psoriasis, an immune-mediated disorder marked by thick, scaly patches called plaques, who are 12 years of age and older.
Also Read: ICRA sees steady growth ahead for Indian pharma industry
According to Liza O'Dowd, Immunodermatology and Respiratory Disease Areas Lead at Johnson & Johnson, icotrokinra is a game changer for patients since it provides efficacy comparable to an injectable biologic with a very favorable safety profile that can be taken orally.According to the National Psoriasis Foundation, more than 8 million Americans suffer from psoriasis.
